Genes2Me rolls out RT PCR based kit for Monkeypox virus

First of its kind `Made in India' product, this kit is available as Research-Use only (RUO) and based on Gold standard Taqman chemistry based RT PCR method

Published On 2022-07-26 11:16 GMT   |   Update On 2022-07-26 11:16 GMT

New Delhi: Genes2Me Pvt. Ltd. has announced that they have developed the Real-Time PCR-based kit for quick detection of Monkeypox virus with fast turnaround result time of less than 50 minutes. This kit is available in both the standard version for any commonly available Real Time PCR instruments as well as Point-of-Care format on Genes2Me Rapi-Q HT Rapid RT-PCR device. The Point-of-Care solution can be used for screening at multiple sites including Hospitals, Airports, Diagnostic Labs, Health Camps, etc.

After more than 16000 cases being reported from 75 countries and territories, WHO has declared the rapidly spreading Monkeypox outbreak a Public Health Emergency of International Concern. "Scientists from Genes2Me have been able to develop "POX-Q Multiplexed RT-PCR kit" for the detection of Monkeypox virus along with differentiation from Varicella Zoster Virus (Chicken Pox) in a single tube multiplex reaction format. First of its kind `Made in India' product, this kit is available as Research-Use only (RUO) and based on Gold standard Taqman chemistry based RT PCR method," that the company stated in its recent release.
The WHO recommended specimen type for laboratory confirmation of Monkeypox is skin lesion material, including swabs of lesion surface and/or exudate, roofs from more than one lesion, or lesion crusts. Hence, for detection of Monkeypox, both dry swabs and swabs placed in VTM can be used.
"This unprecedented time underscores the importance of diagnostic assays in health security preparedness and readiness. We wanted to be prepared ahead of time for this virus. Understanding the value of time, we have launched this RT PCR for Monkeypox which will give the result in less than 50 minutes with the highest accuracy. Genes2Me always strives to bring in revolutionary and path-breaking solutions for critical health conditionswhich can help in the screening of masses during any health emergency."
We have current capacity to manufacture 5 million test kits in a week, however, it can be scaled up to 2 million tests in a day with the added demand said Mr. Neeraj Gupta, CEO and Founder of Genes2Me. He also highlighted that Genes2Me team also introduced "RT-Direct" as first Made-in-India COVID-19 Extraction Free RT-PCR Kit, with coverage of 3 targets specific for SARS-CoV-2 which give results in less than 40 minutes.

Read also: Genes2Me launches CoviEasy Self-Test Kit for COVID

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News